However, in another study, FGF-2 has been reported to be associated with significantly higher FEV1, which indicates lower non-fixed airway obstructive asthma; therefore, the authors consider FGF-2 a protective mediator, which may be considered a target for the treatment of asthma and chronic obstructive pulmonary disease [ 26]. This evidence concerns the gene FGF2 and chronic obstructive pulmonary disease.